Scientific Publications

Legend Biotech sponsors research with academic institutions to evaluate our agents. The manuscripts from this research are presented below.

Year :

Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma

TG Martin, D Madduri, L Pacaud, SZ Usmani

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

J. San‑Miguel, B. Dhakal, K. Yong, A. Spencer, S. Anguille, M.-V. Mateos, C. Fernández de Larrea, J. Martínez‑López, P. Moreau, C. Touzeau, X. Leleu, I. Avivi, M. Cavo, T. Ishida, S.J. Kim, W. Roeloffzen, N.W.C.J. van de Donk, D. Dytfeld, S. Sidana, L.J. Costa, A. Oriol, R. Popat, A.M. Khan, Y.C. Cohen, P.J. Ho, J. […]

Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma

S Palmer, Y Lin, TG Martin, S Jagannath, A Jakubowiak, SZ Usmani, N Buyukkaramikli, H Phelps, R Slowik, F Pan, S Valluri, L Pacaud, G Jackson

Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma

Sundar Jagannath, Nedra Joseph, Concetta Crivera, Akshay Kharat, Carolyn C. Jackson, Satish Valluri, Patricia Cost, Hilary Phelps, Rafal Slowik, Timothy Klein, Lee Smolen, Xueting Yu, Adam D. Cohen

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

MV Mateos, K Weisel, T Martin, JG. Berdeja, A Jakubowiak, AK Stewart, S Jagannath, Y Lin, J Diels, F Ghilotti, P Thilakarathne, NJ Perualila, J Cabrieto, B Haefliger, N Erler-Yates, C Hague, CC Jackson, JM Schecter, V Strulev, T Nesheiwat, L Pacaud, H Einsele, P Moreau